Skip to main content

Table 5 Anemia parameters and the use of ESA and iron

From: Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study

Characteristics Total
(n = 1129)
CKD Stage 3
(n= 434)
CKD Stage 4
(n= 695)
Pvalue
Anemia according to K-DOQI guidelines (%) 51.3 43.7 58.1 0.001
Anemia according to EBPG (%) 30.5 25.5 36.0 0.001
Hemoglobin (g/dL; mean ± SD [range]) 12.8 ± 1.6 [7.6-18.7] 13.2 ± 1.7 [7.6-18.7] 12.4 ± 1.6 [7.6-16.9] 0.001
% of patients with Hemoglobin levels greater than 11 gm/dL 87.8 91.1 85.5 0.001
% of patients with Hemoglobin levels between 9 and 11 gm/dL 11.5 8.6 13.3 0.095
% of patients with Hemoglobin levels less than 9 gm/dL 1.6 0.5 2.3 0.001
Treatment with ESA* (%) 25.5 16.0 34.1 0.001
Mean hemoglobin levels in patients treated with ESA (g/dL; mean ± SD [range]) 12.0 ± 1.5 [7.0-17.4] 12.3 ± 1.5 [9.3-17.4] 12.0 ± 1.5 [7.0-16.2] 0.15
Ferritin (ng/mL; mean ± SD [range]) 150 ± 47 [5-1500] 129 ± 117 [5-997] 169 ± 168 [5-1500] 0.001
Iron (μg/dl; mean ± SD [range]) 70 ± 26 [6-230] 75 ± 28 [6-230] 67 ± 25 [9-197] 0.001
Transferrin saturation < 20% (%) 26.3 23.4 28.5 0.12
Treatment with oral Iron (%) 31.9 23.6 39.5 0.001
Treatment with intravenous Iron (%) 3.0 1.6 4.4 0.001